We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HUM Expands Musculoskeletal Care Access With New Value-Based Tie-Ups
Read MoreHide Full Article
Key Takeaways
Humana partners with Vori Health, HOPCo and TailorCare to expand musculoskeletal care.
Vori will serve nationwide, while HOPCo focuses on Arizona and TailorCare expands to Dallas and Denver.
The initiative aims to cut costs and boost outcomes, supporting Humana's value-based care strategy.
Humana Inc. (HUM - Free Report) recently announced new partnership agreements with Vori Health and Healthcare Outcomes Performance Company (“HOPCo”), which focuses on individual value-based care. This comes along with expanding its existing partnership with TailorCare. The company aims to further enhance care delivery for Medicare Advantage members who are dealing with musculoskeletal conditions like arthritis, osteoporosis and joint disorders.
With this initiative, eligible Humana Medicare Advantage members will have access to coordinated care professionals’ teams with their primary care clinician. Vori Health will offer its services across the country, while HOPCo will focus on providing musculoskeletal care specifically for Medicare Advantage members in Arizona. Additionally, TailorCare, which is currently available in Atlanta, will expand its services in Dallas and Denver in November 2025 and January 2026, respectively.
HUM’s focus on musculoskeletal care is noteworthy as one in two Americans is affected by these conditions. Musculoskeletal disorders are one of the biggest causes of medical expenses for older adults, often resulting in expensive surgeries and hospital stays. HUM will help reduce preventable costs while improving health outcomes by guiding patients with coordinated plans and early interventions.
This strategy fits with Humana’s goals of controlling costs and strengthening its position in the competitive value-based care landscape. The company’s CenterWell segment reported 8.9% year-over-year growth in revenues in the first half of 2025, along with an improved operating cost ratio.
If implemented successfully, these integrations could lead to higher member satisfaction, better retention rates and improved margins over time. This strategic decision might strengthen HUM’s long-term growth approach while addressing the increasing need for holistic, specialized healthcare solutions.
HUM Stock Price Performance
Year to date, HUM’s shares have gained 17% against the industry’s decline of 31.6%.
The Zacks Consensus Estimate for Tenet Healthcare’s current-year earnings of $15.54 per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. Tenet Healthcare beat earnings estimates in each of the trailing four quarters, with the average surprise being 31.2%. The consensus estimate for current-year revenues is pegged at $21.2 billion, suggesting 2.4% year-over-year growth.
The Zacks Consensus Estimate for Avadel Pharmaceuticals’ current-year earnings of 26 cents per share has witnessed four upward revisions in the past 30 days against no movement in the opposite direction. Avadel Pharmaceuticals beat earnings estimates in three of the trailing four quarters and met once, with the average surprise being 119.6%. The consensus estimate for current-year revenues is pegged at $274.1 million, suggesting 62.1% year-over-year growth.
The Zacks Consensus Estimate for InfuSystem Holdings’ current-year earnings of 26 cents per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. InfuSystem Holdings beat earnings estimates in two of the trailing four quarters, missed once and met once, with an average surprise being 79.2%. The consensus estimate for current-year revenues is pegged at $144.2 million, suggesting 6.9% year-over-year growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
HUM Expands Musculoskeletal Care Access With New Value-Based Tie-Ups
Key Takeaways
Humana Inc. (HUM - Free Report) recently announced new partnership agreements with Vori Health and Healthcare Outcomes Performance Company (“HOPCo”), which focuses on individual value-based care. This comes along with expanding its existing partnership with TailorCare. The company aims to further enhance care delivery for Medicare Advantage members who are dealing with musculoskeletal conditions like arthritis, osteoporosis and joint disorders.
With this initiative, eligible Humana Medicare Advantage members will have access to coordinated care professionals’ teams with their primary care clinician. Vori Health will offer its services across the country, while HOPCo will focus on providing musculoskeletal care specifically for Medicare Advantage members in Arizona. Additionally, TailorCare, which is currently available in Atlanta, will expand its services in Dallas and Denver in November 2025 and January 2026, respectively.
HUM’s focus on musculoskeletal care is noteworthy as one in two Americans is affected by these conditions. Musculoskeletal disorders are one of the biggest causes of medical expenses for older adults, often resulting in expensive surgeries and hospital stays. HUM will help reduce preventable costs while improving health outcomes by guiding patients with coordinated plans and early interventions.
This strategy fits with Humana’s goals of controlling costs and strengthening its position in the competitive value-based care landscape. The company’s CenterWell segment reported 8.9% year-over-year growth in revenues in the first half of 2025, along with an improved operating cost ratio.
If implemented successfully, these integrations could lead to higher member satisfaction, better retention rates and improved margins over time. This strategic decision might strengthen HUM’s long-term growth approach while addressing the increasing need for holistic, specialized healthcare solutions.
HUM Stock Price Performance
Year to date, HUM’s shares have gained 17% against the industry’s decline of 31.6%.
Image Source: Zacks Investment Research
HUM’s Zacks Rank & Key Picks
HUM currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Medical space are Tenet Healthcare Corporation (THC - Free Report) , Avadel Pharmaceuticals plc (AVDL - Free Report) and InfuSystem Holdings, Inc. (INFU - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Tenet Healthcare’s current-year earnings of $15.54 per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. Tenet Healthcare beat earnings estimates in each of the trailing four quarters, with the average surprise being 31.2%. The consensus estimate for current-year revenues is pegged at $21.2 billion, suggesting 2.4% year-over-year growth.
The Zacks Consensus Estimate for Avadel Pharmaceuticals’ current-year earnings of 26 cents per share has witnessed four upward revisions in the past 30 days against no movement in the opposite direction. Avadel Pharmaceuticals beat earnings estimates in three of the trailing four quarters and met once, with the average surprise being 119.6%. The consensus estimate for current-year revenues is pegged at $274.1 million, suggesting 62.1% year-over-year growth.
The Zacks Consensus Estimate for InfuSystem Holdings’ current-year earnings of 26 cents per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. InfuSystem Holdings beat earnings estimates in two of the trailing four quarters, missed once and met once, with an average surprise being 79.2%. The consensus estimate for current-year revenues is pegged at $144.2 million, suggesting 6.9% year-over-year growth.